최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.27 no.4, 2017년, pp.199 - 206
이영미 (충남대학교 약학대학) , 윤휘열 (충남대학교 약학대학)
As the population ages, the life of women after menopause becomes much longer than the past, and the quality of life of old age becomes increasingly principal issue. There is a period that women experience the physical symptoms of menopause, although there are differences in degree, and the manageme...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
MHT의 장점은 무엇인가? | MHT는 폐경기 증상완화에 효과적인 약물로 알려져 있고 장기적인 사용으로 골밀도를 높여 골다공증의 발생을 줄이는 효과를 가지고 있다. 그러나 부작용으로 나타날 수 있는 혈전 생성, 심혈관질환 유발, 유방암 발생 증가 등에 대한 우려들도 있는 것이 사실이다. | |
폐경기에 접어드는 여성들이 estradiol과 estrone의 비율이 변화되면서 겪게 되는 증상은 무엇인가? | 정상적인 폐경 전 여성에서 estradiol과 estrone의 비율은 2:1 인 반면, 폐경기에 접어드는 여성들은 이 비율이 변화되면서 여러 임상증상들을 경험하게 된다.1) 주로 호소하게 되는 증상으로는 혈관 운동 증상(안면홍조, 두통, 발한), 질건조감, 질소양감, 불안, 불면, 우울증 등이다. 폐경기 여성들은 이러한 임상증상으로 인한 직접적인 불편감(근육통, 관절통증 등)을 호소할 수 있으며, 증상 지속으로 인한 삶의 질 저하 등의 문제가 발생할 수 있다. | |
여성 호르몬 estrogen의 종류는 무엇인가? | 여성 호르몬 estrogen은 크게 estriol, estradiol, estrone 3종류가 있다. 생식이 가능한 건강한 여성의 경우 estradiol이 가장 많은 형태의 호르몬으로 콜레스테롤에서 androgen을 거쳐 난소에서 생성된다. |
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(suppl 1):3-63.
Yoon BK. Development of the protocol to evaluate the effects of hormone therapy in postmenopausal women. The 3rd Symposium on Women's Health Research. 2014.9.26
Available from http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do
Cho MK, Park HM. The National Use of Hormonal Therapy in Postmenopausal Women in 2010. J Korean Soc Menopause 2011; 17:150-4.
Han KO. Postmenopausal Hormone Therapy Up-to-date. The Korean Journal of Endocrinology 2007;22(5).
Park HM. Female hormone therapy tendency after WHI. The Korean Clinical Elderly Medical Society. In: Fall Conference 2006.
Miller VM, Jenkins GD, Biernacka JM, et al. Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiol Genomics 2016;48(1):33-41.
Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med 2016;374(13):1221-31.
Gallagher JC, Palacios S, Ryan KA, et al. Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. Menopause 2016;23(10):1083-91.
Cintron D, Lahr BD, Bailey KR, et al. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause 2017 Aug 21.
Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8(1):3-12.
Kling JM, Lahr BA, Bailey KR, et al. Endothelial function in women of the Kronos Early Estrogen Prevention Study. Climacteric 2015;18(2):187-97.
Santoro N, Allshouse A, Neal-Perry G, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause 2017;24(3):238-46.
Gleason CE, Dowling NM, Wharton W, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Med 2015;12(6):e1001833.
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310(13):1353-68.
Lindsay R, Gallagher JC, Kleerekoper M, et al. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16(4):372-9.
Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;20:59(1):2-6.
Sturdee DW, Archer DF, Rakov V, et al. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric 2008;11(1):63-73.
De Franciscis P, Cobellis L, Fornaro F, et al. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet 2007;98(2):138-42.
Sturdee DW, Pines A; International Menopause Society Writing Group, Archer DF, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14: 302-20.
Bodmer C, Steimann S, Schiessl K, et al. Hormonersatztherapie (HET) - Guidelines fur die Schweiz. Gynakol Endokrinol 2009;3:26-30
Coelingh Bennink HJ. Are all estrogens the same? Maturitas 2004;47(4):269-75.
Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause 2002;9(4):253-63.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treatment 2008;107:103-11.
Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488-93.
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5.
Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.
Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. Women's Health 2006;15:35-44.
Stute P, Becker HG, Bitzer J, et al. Ultra-low dose - new approaches in menopausal hormone therapy. Climacteric 2015;18(2):182-6.
North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-71.
Marjoribanks J, Farquhar CM, Roberts H, et al. Cochrane corner: longterm hormone therapy for perimenopausal and postmenopausal women. Heart 2017 Jul 24.
Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause- 2017 update. Endocr Pract 2017;23(7):869-80.
Manassiev N, Godsland IF, Anthony J, et al. Effects of tibolone or continuous combined oestradiol/norethisterone acetate on glucose and insulin metabolism. Clinical Endocrinology 2013;78:297-302.
Inan I, Kelekci S, Yilmaz B. Psychological effects of tibolone and sequential estrogen-progestogen therapy in perimenopausal women. Gynecol Endocrinol 2005;20(2):64-7.
Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016;10:CD008536.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.